Zealand Pharma A/S (OTCMKTS:ZLDPF) Posts Earnings Results, Beats Expectations By $0.53 EPS

Posted by Grant Hamersma on Feb 21st, 2026

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.53, Zacks reports. The firm had revenue of $10.79 million for the quarter, compared to the consensus estimate of $19.69 million. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 49.76%.

Zealand Pharma A/S Stock Performance

ZLDPF opened at $60.42 on Friday. The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02. The stock’s 50 day simple moving average is $68.29 and its 200-day simple moving average is $70.44. The stock has a market cap of $4.29 billion, a PE ratio of 4.42 and a beta of 0.72. Zealand Pharma A/S has a 1 year low of $49.98 and a 1 year high of $101.29.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. BTIG Research upgraded Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research note on Tuesday, December 16th. Five research analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy”.

Read Our Latest Stock Analysis on ZLDPF

About Zealand Pharma A/S

(Get Free Report)

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.